Global biopharmaceutical leader Bristol Myers Squibb (BMS) recently announced a strategic agreement with AI company Anthropic to deploy Claude Enterprise as a shared intelligence platform across its global operations. The partnership covers core departments including R&D, clinical development, manufacturing, commercial, and corporate functions, marking a pivotal step in the real-world application of AI within large pharma.
Under the agreement, BMS will leverage Claude’s agentic capabilities rather than limited conversational interactions. By securely integrating with the company’s vast data sources and knowledge bases, Claude can automatically generate clinical study reports, accurately extract scientific context from decades of internal research, and even trace root causes of manufacturing deviations in real time. Eric Kauderer-Abrams, Anthropic’s head of life sciences, described this as building a unified intelligence layer for BMS—enabling institutional knowledge to be activated instantly when needed, all under enterprise-grade governance and audit controls.
